PUBLISHER: The Insight Partners | PRODUCT CODE: 1874006
PUBLISHER: The Insight Partners | PRODUCT CODE: 1874006
The cell therapy market is anticipated to grow from US$ 10.28 billion in 2024 to US$ 16.72 billion by 2031, reflecting a compound annual growth rate (CAGR) of 7.2% during the period from 2031 to 2031. Key trends driving this market include advancements in cell-based therapeutics and the launch of innovative products by leading manufacturers.
Analysis of the Cell Therapy Market
Regenerative therapies promote the regeneration of cells, tissues, and organs, facilitating the restoration of their functions. As reported by the Alliance for Regenerative Medicine, there were 520 clinical trials involving cell therapy medicines globally as of Q4 2023 (comprising 192 Phase I, 125 Phase II, and 36 Phase III trials). The approval and commercialization of Kymriah in 2017, the first of its kind in cell therapy, marked a pivotal moment that has bolstered the significance of cell therapy within the cell and gene therapy sector. The advent of CAR-T cell (chimeric antigen receptor T cell) therapy has revolutionized cancer treatment approaches. CAR-T cell therapies have seen extensive research and innovation, with five additional products-Yescarta, Abecma, Tecartus, Breyanzi, and Carvykti-receiving approval for various blood cancers. Consequently, the expanding applications of regenerative medicine are propelling the growth of the cell therapy market.
Overview of the Cell Therapy Market
CAR T-cell therapy has emerged as a promising cancer treatment modality. Each year, numerous preclinical and clinical trials are conducted to explore its potential in new therapeutic applications. Future research is expected to focus on both autologous and allogeneic products, as well as new in-vivo CAR-T cell gene therapies and their effectiveness in conditions beyond hematologic malignancies.
Strategic Insights
Drivers and Opportunities in the Cell Therapy Market
Rising Cancer Prevalence Fuels Market Expansion
Factors such as sedentary lifestyles and dietary changes are recognized as significant risk factors for chronic diseases, including neurological disorders, cancer, autoimmune diseases, and cardiovascular diseases. The Centers for Disease Control and Prevention reports that 6 out of 10 Americans are affected by one or more chronic illnesses, including diabetes, cancer, heart disease, or stroke. Chronic diseases are leading causes of death and disability in the US. Factors like genetic predisposition, processed foods, pollution, and lifestyle changes contribute to the increasing incidence of cancer. The American Cancer Society noted nearly 19.3 million new cancer cases worldwide in 2020. In recent decades, cell therapy has emerged as a novel cancer treatment approach, where T cells are modified in a lab and then administered to target cancer cells. CAR-T cell therapy is utilized for treating adult and pediatric leukemia and certain types of lymphoma, with ongoing research into its potential for treating other cancers, including solid tumors. Thus, the rising number of cancer patients is driving demand for CAR-T cell therapies, contributing to the growth of the cell therapy market.
Funding for Research and Development
Researchers are driven to explore ways to enhance the efficacy of cell therapy, particularly given the complete response rates and progression-free survival seen in patients with relapsed/refractory malignancies who have undergone prior treatments. Investigations into factors like antigen loss that may lead to immune escape are underway, with strategies being developed to address these challenges. One promising approach involves designing cell therapies that target multiple antigens simultaneously. The California Institute for Regenerative Medicine (CIRM), the largest regenerative medicine organization globally, has allocated US$ 43.8 million to support gene therapy and stem cell research initiatives in California, funding projects across clinical, discovery, and infrastructure programs of the institute.
Segmentation Analysis of the Cell Therapy Market
Key segments contributing to the analysis of the cell therapy market include therapy type, product, technology, application, and end user.
Geographical Analysis of the Cell Therapy Market
The geographical scope of the cell therapy market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. North America leads the market, with the US holding the largest share in 2023. This growth is attributed to increased research and development, along with the rising adoption of cell therapies such as stem cell, gene, and immune therapies. The growing incidence of genetic and cellular disorders, coupled with a focus on enhancing the development and manufacturing capacities of cell therapies, further supports market growth. Bayer AG has established its first Cell Therapy Launch Facility in Berkeley, aimed at delivering cell therapies to patients globally. This US$ 250 million, 100,000-square-foot facility will provide materials for late-stage clinical trials to facilitate the commercial launch of bemdaneprocel (BRT-DA01), an experimental cell therapy being tested by BlueRock Therapeutics for Parkinson's disease and other conditions. The Asia Pacific region is expected to exhibit the highest CAGR in the cell therapy market during the forecast period.
Scope of the Cell Therapy Market Report
Recent Developments in the Cell Therapy Market
The evaluation of the cell therapy market is based on qualitative and quantitative data obtained from primary and secondary research, including significant corporate publications, association data, and databases. Some recent developments in the cell therapy market include:
Coverage and Deliverables of the Cell Therapy Market Report
The report titled "Cell Therapy Market Size and Forecast (2021-2031)" provides a comprehensive analysis of the market, covering the following areas: